Atogepant

Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.[1][2]

Atogepant
Clinical data
Trade namesQulipta
Other namesAGN-241689, MK-8031
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
  • (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H23F6N5O3
Molar mass603.525 g·mol−1
3D model (JSmol)
  • C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F
  • InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1
  • Key:QIVUCLWGARAQIO-OLIXTKCUSA-N

It was approved for medical use in the United States in September 2021.[1][3]

References

  1. "Qulipta- atogepant tablet". DailyMed. Retrieved 31 October 2021.
  2. Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ (June 2020). "Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?". Current Opinion in Neurology. 33 (3): 309–315. doi:10.1097/WCO.0000000000000806. PMID 32251023. S2CID 215408433.
  3. "FDA Approves Qulipta (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine". AbbVie (Press release). 28 September 2021. Retrieved 29 September 2021 via PR Newswire.
  • "Atogepant". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.